Taysha Gene Therapies is a pre-commercial gene therapy company with 78% analyst-implied upside, a 2.3x volume surge on recent upward moves, and a strongly bullish technical breakout — but its cash-burning status, below-quality-floor metrics, and extreme put/call ratio of 30.20 reflect the high binary risk of a development-stage biotech.
Thesis pillars
- Large Analyst Upside Gene Therapy→Stable
- Cash Burn Clinical Stage Risk→Stable
- Extreme Put Call Ratio Binary Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.55: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.90; Below-average business quality.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for... Read more
Sell if holding. Engine safety override at $6.55: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.90; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Score 5.4/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-06Recent Developments — Taysha Gene Therapies, Inc.
Latest news
- NEWS Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target — benzinga Jul 2, 2026 positive
- NEWS Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga Jun 30, 2026 neutral
- NEWS Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15 — benzinga Jun 30, 2026 positive
- NEWS H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session — benzinga Jun 25, 2026 neutral
- NEWS Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket — benzinga Jun 25, 2026 neutral
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 6.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.55: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 1.90; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Prior stop was $6.07. Score 5.4/10, moderate confidence.
Take-profit target: $11.31 (+73.2% upside). Prior stop was $6.07. Stop-loss: $6.07.
Quality below floor (3.3 < 4.0).
Taysha Gene Therapies, Inc. trades at a P/E of N/A (forward -15.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover TSHA with a consensus score of 4.3/5. Average price target: $13.
What does Taysha Gene Therapies, Inc. do?Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing...
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.